Publications by authors named "Keiko Inomata"
This study aimed to determine whether additional tissue sampling of encapsulated thyroid nodules would increase the frequency of follicular thyroid carcinoma (FTC) diagnoses. We examined thyroid tissue specimens from 86 patients suspected of FTC (84.9% female; mean age, 49.
View Article and Find Full Text PDFImmunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibro-inflammatory condition that often causes the formation of tumefactive lesions. The discovery of IgG4-RD linked many well-known isolated conditions as a distinct multi-organ disease, and started an era of promoting investigation and treatment in relevant fields. In the thyroid gland, a subcategory of Hashimoto thyroiditis (HT) with IgG4-rich inflammation was first discovered and named IgG4 thyroiditis by our group.
View Article and Find Full Text PDFArticle Synopsis
- A new automated electrochemiluminescence immunoassay has been developed to quickly measure TSH receptor autoantibodies (TRAb) in patients.
- This assay was tested in a multicenter international trial involving various thyroid conditions and showed high sensitivity and specificity, particularly for Graves' disease.
- The study concludes that this assay could become the standard for fast and accurate TRAb detection, distinguishing it effectively from other thyroid diseases.
Article Synopsis
- Graves' disease (GD) is linked to autoantibodies that target the TSH receptor, and this study aimed to assess a new automated immunoassay (Elecsys Anti-TSHR) for detecting these antibodies.
- The test showed acceptable levels of precision with a functional sensitivity of 0.73 IU/L and strong correlation with existing TRAb immunoassays, indicating its effectiveness.
- The new automated assay demonstrated high sensitivity (97%) and specificity (99%) for diagnosing GD, marking a significant improvement in thyroid testing practices.
Background: Hyperthyroidism in Graves' disease is caused by autoantibodies to the TSH receptor (TSHR), and measurement of the TSHR autoantibody (TRAb) yields important information to diagnose and decide on the course of treatment of Graves' disease. We evaluated basic and clinical performance of a new, rapid, and fully automated electrochemiluminescence immunoassay Elecsys Anti-TSHR (Elecsys TRAb) for measuring serum TRAb.
Methods: For evaluation of basic performance of the assay, we carried out intra- and interassay precision studies using five serum pools and three serum pools, respectively, and the assay was compared with four commercial TRAb assays.